Bark Inc’s 24% share-price advance on Tuesday prompted Jefferies analysts to slap a ‘Hold’ rating on the stock but still see 42% upside for the dog-centric products and services company.
"Discretionary toy demand is still challenged; however, several actions to drive efficiency should cleanup operations and deliver consistent profitability, better positioning the company," the analysts wrote in a note to clients.
Birkenstock is scheduled to report quarterly earnings for the first time since its October IPO before the market opens on January 18.
The iconic German shoe company is projected to post fiscal 2023 fourth-quarter earnings of $0.18 per share on revenue of $391.16 million.
Zillow (NASDAQ:Z) shares have priced in a steady recovery in housing in 2024 and near record low home affordability could limit volume upside, Bank of America analysts acknowledged.
In downgrading Zillow (NASDAQ:Z) stock to ‘Neutral’ from ‘Buy’, the analysts also cited real estate commission lawsuits as being an overhang on Zillow's buy side agent lead generation segment, which make up nearly 50% of the company’s revenues.
Aclaris Therapeutics shares plunged more than 24% Wednesday after the company’s mild to severe atopic dermatitis (AD) treatment received disappointing topline results.
The results from the 4-week Phase 2b trial of its ATI-1777 treatment were not statistically superior to the Phase 2a trial, according to chairman Neal Walker.
IMI, Endeavour Mining, Harbour Energy and Jet2 are among the top 10 share picks for 2024 from analysts at Stifel, who were asked for the best investment ideas from their sectors.
Analysts at the investment bank each choose their top stock from their coverage, led by head of research and industrials analyst Mark Davies Jones, who chose IMI PLC (LSE:IMI) for its premium profit margins at a discount valuation – “a rare combination in this sector”.
Greggs PLC (LSE:GRG)’s fourth-quarter trading update was warmly welcomed by analysts on Wednesday as the bakery chain unveiled a jump in revenue.
A jump in like-for-like sales caught the eyes of many, given the figure came in 13.7% higher for the year and up 9.4% in the final quarter.
Match Group (NASDAQ:MTCH) Inc’s stock price could get a lift in 2024 by important catalysts including an activist investor and a new Tinder CEO, Jefferies analysts asserted.
In an update to clients, the analysts raised their price target on Match Group (NASDAQ:MTCH) stock to $47 per share while maintaining a ‘Buy’ rating, implying 20% upside from current levels, believing the stock will be rewarded more for accelerating user/revenue growth than cost-cutting.
GSK has received a healthy price target upgrade from analysts at Deutsche Bank, which has the UK pharma as a top pick in a sector with a mixed outlook in 2024.
“Top-down, our sector view remains neutral and perhaps even more incrementally cautious for 2023 relative to FY23; however we do have a very clear rank order of preferences, with Novo, GSK and Novartis our buy recommendations.”
Solo Brands' (NYSE:DTC) announcement that CEO John Merris is on his way out, shortly after the company made a significant revision to its 2023 revenue and earnings guidance, has forced analysts at Jefferies to reassess their valuation of the company.
While the analysts continue to view the company’s portfolio of lifestyle brands as strong, they said it was “prudent” to move to the sidelines until its go-forward strategy is better understood.
Stifel analysts have thrown their weight behind a cohort of cyclical and undervalued UK technology stocks in what is otherwise expected to be a challenging trading environment.
Among the mid caps, analysts graced information technology and software group Kainos Group PLC (LSE:KNOS) with a 'buy' recommendation “as the company prepares for a new cycle of growth that we think will begin to emerge by year end, helping its share price”.
Bayer AG (ETR:BAYN, OTC:BAYZF) will find it tough to hit last year's targets and faces multiple adverse factors in 2024, said Stifel as it downgraded the German pharma giant and cut its share price target.
The US bank removed its 'buy' rating with a switch to a 'hold' stance with a reduced price target of €42 from €68.